Sialic Acid-Binding Ig-like Lectin 15

<strong>Sialic Acid-Binding Ig-like Lectin 15</strong>_x000D_ <strong>Catalog number:</strong> B2013136_x000D_ <strong>Lot number:</strong> Batch Dependent_x000D_ <strong>Expiration Date:</strong> Batch dependent_x000D_ <strong>Amount:</strong> 10 ug_x000D_ <strong>Molecular Weight or Concentration:</strong> N/A_x000D_ <strong>Supplied as:</strong> Lyophilized Powder_x000D_ <strong>Applications:</strong> molecular tool for various biochemical applications_x000D_ <strong>Storage:</strong> -20°C_x000D_ <strong>Keywords:</strong> SIGLEC15_x000D_ <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity &gt;18 MΩ-cm) and are filtered through 0.22 um._x000D_ _x000D_ <strong>References:</strong>_x000D_ 1: Reily C, Stewart TJ, Renfrow MB, Novak J. Glycosylation in health and disease Nat Rev Nephrol. 2019 Jun;15(6):346-366._x000D_ 2: Li B, Zhang B, Wang X, Zeng Z, Huang Z, Zhang L, Wei F, Ren X, Yang L. Expression signature, prognosis value, and immune characteristics of Siglec-15 identified by pan-cancer analysis Oncoimmunology. 2020 Aug 28;9(1):1807291._x000D_ 3: Kantarjian HM, DeAngelo DJ, Stelljes M, Martinelli G, Liedtke M, Stock W, Gökbuget N, O'Brien S, Wang K, Wang T, Paccagnella ML, Sleight B, Vandendries E, Advani AS. Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia N Engl J Med. 2016 Aug 25;375(8):740-53._x000D_ 4: Fry TJ, Shah NN, Orentas RJ, Stetler-Stevenson M, Yuan CM, Ramakrishna S, Wolters P, Martin S, Delbrook C, Yates B, Shalabi H, Fountaine TJ, Shern JF, Majzner RG, Stroncek DF, Sabatino M, Feng Y, Dimitrov DS, Zhang L, Nguyen S, Qin H, Dropulic B, Lee DW, Mackall CL. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy Nat Med. 2018 Jan;24(1):20-28._x000D_ 5: Rashid S, Song D, Yuan J, Mullin BH, Xu J. Molecular structure, expression, and the emerging role of Siglec-15 in skeletal biology and cancer J Cell Physiol. 2022 Mar;237(3):1711-1719._x000D_ 6: Tan YQ, Li YT, Yan TF, Xu Y, Liu BH, Yang JA, Yang X, Chen QX, Zhang HB. Six Immune Associated Genes Construct Prognostic Model Evaluate Low-Grade Glioma Front Immunol. 2020 Dec 21;11:606164._x000D_ 7: Cordoba S, Onuoha S, Thomas S, Pignataro DS, Hough R, Ghorashian S, Vora A, Bonney D, Veys P, Rao K, Lucchini G, Chiesa R, Chu J, Clark L, Fung MM, Smith K, Peticone C, Al-Hajj M, Baldan V, Ferrari M, Srivastava S, Jha R, Arce Vargas F, Duffy K, Day W, Virgo P, Wheeler L, Hancock J, Farzaneh F, Domning S, Zhang Y, Khokhar NZ, Peddareddigari VGR, Wynn R, Pule M, Amrolia PJ. CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial Nat Med. 2021 Oct;27(10):1797-1805._x000D_ 8: Hiruma Y, Hirai T, Tsuda E. Siglec-15, a member of the sialic acid-binding lectin, is a novel regulator for osteoclast differentiation Biochem Biophys Res Commun. 2011 Jun 10;409(3):424-9._x000D_ 9: Chen X, Mo S, Zhang Y, Ma H, Lu Z, Yu S, Chen J. Analysis of a novel immune checkpoint, Siglec-15, in pancreatic ductal adenocarcinoma J Pathol Clin Res. 2022 May;8(3):268-278._x000D_ <a href="https://pubmed.ncbi.nlm.nih.gov/33725422">10: Liu S, Deng B, Yin Z, Lin Y, An L, Liu D, Pan J, Yu X, Chen B, Wu T, Chang AH, Tong C. Combination of CD19 and CD22 CAR-T cell therapy in relapsed B-cell acute lymphoblastic leukemia after allogeneic transplantation Am J Hematol. 2021 Jun 1;96(6):671-679. </a>_x000D_ _x000D_ <strong>Products Related to Sialic Acid-Binding Ig-like Lectin 15 can be found at</strong> <a href="https://moleculardepot.com/product-category/Conjugates/"> Conjugates</a>